Created at	Source	Raw Value	Validated value
June 25, 2024, noon	usa	* known severe allergic reactions to tocilizumab or any other monoclonal antibody * pregnancy or breastfeeding * absolute neutrophil count(anc) \< 1000 * alanine aminotransferase(alt) or aspartate aminotransferase (ast) \> 5 times upper normal limit * platelet count of \< 50,000 * bowel diverticulitis or bowel perforation * patients having acute pancreatitis	* known severe allergic reactions to tocilizumab or any other monoclonal antibody * pregnancy or breastfeeding * absolute neutrophil count(anc) \< 1000 * alanine aminotransferase(alt) or aspartate aminotransferase (ast) \> 5 times upper normal limit * platelet count of \< 50,000 * bowel diverticulitis or bowel perforation * patients having acute pancreatitis
Jan. 30, 2021, 12:31 a.m.	usa	- known severe allergic reactions to tocilizumab or any other monoclonal antibody - pregnancy or breastfeeding - absolute neutrophil count(anc) < 1000 - alanine aminotransferase(alt) or aspartate aminotransferase (ast) > 5 times upper normal limit - platelet count of < 50,000 - bowel diverticulitis or bowel perforation - patients having acute pancreatitis	- known severe allergic reactions to tocilizumab or any other monoclonal antibody - pregnancy or breastfeeding - absolute neutrophil count(anc) < 1000 - alanine aminotransferase(alt) or aspartate aminotransferase (ast) > 5 times upper normal limit - platelet count of < 50,000 - bowel diverticulitis or bowel perforation - patients having acute pancreatitis